ROIV

Roivant Sciences Ltd

Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) CAO Jennifer Humes sold 13,538 shares of the stock in a transaction on Wednesday, April 8th. The stock was sold at an average price of $28.37...

Montes Archimedes Acquisition (ROIV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Capricorn Fund Managers Ltd raised its stake in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 124.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities...

Roivant Sciences and Priovant Therapeutics executives outlined an expansion of the brepocitinib development program into lichen planopilaris (LPP) and discussed newly released Phase 3 results for batoclimab in thyroid eye disease (TED), which failed to meet its primary endpoint. Brepocitinib expand...

Roivant Sciences (NASDAQ:ROIV) outlined plans to expand development of its JAK1/TYK2 inhibitor brepocitinib into lichen planopilaris (LPP) and provided an update on a Phase III thyroid eye disease (TED) trial for batoclimab during a conference call hosted by the company. Brepocitinib expands into l...

Exchange Traded Concepts LLC acquired a new position in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 250,468 shares of the company's stock, valued at a...

Assenagon Asset Management S.A. grew its holdings in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 11,507.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 6,937,112 shares of the company's s...

Shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) have earned an average rating of "Moderate Buy" from the eleven ratings firms that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendat...

Sanford C. Bernstein initiated coverage on shares of Roivant Sciences in a research note on Friday. They set an "outperform" rating and a $35.00 target price for the company...